Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

November 9, 2025

Study Completion Date

December 19, 2025

Conditions
Glioblastoma MultiformeDiffuse Midline Glioma, H3 K27M-MutantGliosarcomaGiant Cell GlioblastomaGBM
Interventions
BIOLOGICAL

S-Gboxin

Gboxin specifically inhibits the growth of human glioblastoma cells but not normal cells. Gboxin rapidly and irreversibly impairs oxygen consumption in glioblastoma cells. Its positive charge for binding to mitochondrial oxidative phosphorylation complexes is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits F 0 F 1 ATP synthase activity in tumor cells. S-Gboxin crosses the blood-brain barrier at therapeutically effective concentrations.

Trial Locations (3)

0198

Tbilisi Cancer Centre, Tbilisi

490 078

Kazakh Institute of Oncology and Radiology, Almaty

33/43

National Cancer Institute, Kyiv

All Listed Sponsors
collaborator

Lytvin,Ruslan

UNKNOWN

lead

Petrov, Andrey

OTHER